Compare Stocks: PACB, TXG, AZTA, and CYRX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AZTA Azenta	$34.28 +1.6%	$31.33	$15.93 ▼ $41.73	$1.48B	1.39	782,641 shs	1.13 million shs
CYRX CryoPort	$17.57 -0.3%	$15.85	$7.61 ▼ $17.85	$892.44M	1.89	489,025 shs	587,951 shs
PACB Pacific Biosciences of California	$1.47 +8.1%	$1.34	$1.07 ▼ $2.73	$422.73M	2.31	5.57 million shs	7.84 million shs
TXG 10x Genomics	$80.70 +2.0%	$58.51	$11.16 ▼ $82.68	$10.31B	2.08	2.55 million shs	3.89 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AZTA Azenta	+1.57%	+3.78%	-8.34%	+43.62%	+9.24%
CYRX CryoPort	-0.28%	+7.73%	+2.57%	+13.21%	+73.45%
PACB Pacific Biosciences of California	+8.09%	+9.70%	+8.89%	+2.08%	+13.95%
TXG 10x Genomics	+2.02%	+8.48%	+23.93%	+133.38%	+518.87%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AZTA Azenta	$34.28 +1.6%	$31.33	$15.93 ▼ $41.73	$1.48B	1.39	782,641 shs	1.13 million shs
CYRX CryoPort	$17.57 -0.3%	$15.85	$7.61 ▼ $17.85	$892.44M	1.89	489,025 shs	587,951 shs
PACB Pacific Biosciences of California	$1.47 +8.1%	$1.34	$1.07 ▼ $2.73	$422.73M	2.31	5.57 million shs	7.84 million shs
TXG 10x Genomics	$80.70 +2.0%	$58.51	$11.16 ▼ $82.68	$10.31B	2.08	2.55 million shs	3.89 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AZTA Azenta	+1.57%	+3.78%	-8.34%	+43.62%	+9.24%
CYRX CryoPort	-0.28%	+7.73%	+2.57%	+13.21%	+73.45%
PACB Pacific Biosciences of California	+8.09%	+9.70%	+8.89%	+2.08%	+13.95%
TXG 10x Genomics	+2.02%	+8.48%	+23.93%	+133.38%	+518.87%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AZTA Azenta	2.43	Hold	$41.20	20.19% Upside
CYRX CryoPort	2.67	Moderate Buy	$18.00	2.45% Upside
PACB Pacific Biosciences of California	1.83	Reduce	$1.71	16.50% Upside
TXG 10x Genomics	2.24	Hold	$44.00	-45.48% Downside

Current Analyst Ratings Breakdown

Latest PACB, TXG, AZTA, and CYRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/18/2026	CYRX CryoPort	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$25.00
9/14/2026	AZTA Azenta	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$37.00
9/10/2026	PACB Pacific Biosciences of California	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/9/2026	PACB Pacific Biosciences of California	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Neutral	$1.50 ➝ $1.35
9/9/2026	TXG 10x Genomics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Neutral	$20.00 ➝ $68.00
9/1/2026	TXG 10x Genomics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Sector Perform	$70.00
9/1/2026	TXG 10x Genomics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Sector Perform	$70.00
8/26/2026	AZTA Azenta	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/25/2026	PACB Pacific Biosciences of California	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/17/2026	CYRX CryoPort	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C-) ➝ Sell (D)
8/12/2026	TXG 10x Genomics	Stephens Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$50.00 ➝ $65.00

(Data available from 9/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AZTA Azenta	$593.82M	2.53	$1.84 per share	18.62	$37.67 per share	0.91
CYRX CryoPort	$176.18M	5.05	N/A	N/A	$9.19 per share	1.91
PACB Pacific Biosciences of California	$160.01M	2.86	$0.85 per share	1.72	$0.02 per share	73.50
TXG 10x Genomics	$642.82M	16.36	N/A	N/A	$6.24 per share	12.93

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AZTA Azenta	-$55.76M	-$2.76	N/A	N/A	N/A	-20.63%	1.18%	0.97%	11/20/2026 (Estimated)
CYRX CryoPort	$78.30M	-$0.90	N/A	N/A	N/A	-20.05%	-7.20%	-4.30%	11/3/2026 (Estimated)
PACB Pacific Biosciences of California	-$546.38M	-$0.43	N/A	N/A	N/A	-82.49%	-5,752.12%	-19.52%	11/3/2026 (Estimated)
TXG 10x Genomics	-$43.54M	-$0.59	N/A	N/A	N/A	-12.18%	-9.33%	-7.30%	11/5/2026 (Estimated)

Latest PACB, TXG, AZTA, and CYRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	CYRX CryoPort	-$0.1933	-$0.20	-$0.0067	-$0.20	$48.18 million	$48.97 million
8/6/2026	Q2 2026	TXG 10x Genomics	-$0.2431	-$0.14	+$0.1031	-$0.14	$146.67 million	$151.04 million
8/4/2026	Q3 2026	AZTA Azenta	$0.1138	$0.16	+$0.0462	$0.05	$149.31 million	$161.18 million
8/3/2026	Q2 2026	PACB Pacific Biosciences of California	-$0.1280	-$0.14	-$0.0120	-$0.14	$42.90 million	$39.01 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AZTA Azenta	N/A	N/A	-100.00%	N/A	N/A
CYRX CryoPort	N/A	N/A	N/A	N/A	N/A
PACB Pacific Biosciences of California	N/A	N/A	N/A	N/A	N/A
TXG 10x Genomics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AZTA Azenta	N/A	2.50	2.21
CYRX CryoPort	N/A	2.08	1.98
PACB Pacific Biosciences of California	N/A	4.92	4.03
TXG 10x Genomics	N/A	5.69	5.25

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AZTA Azenta	99.08%
CYRX CryoPort	92.90%
PACB Pacific Biosciences of California	N/A
TXG 10x Genomics	84.68%

Insider Ownership

Company	Insider Ownership
AZTA Azenta	10.90%
CYRX CryoPort	9.50%
PACB Pacific Biosciences of California	3.70%
TXG 10x Genomics	8.84%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AZTA Azenta	3,000	43.81 million	39.03 million	Optionable
CYRX CryoPort	738	50.65 million	45.84 million	Optionable
PACB Pacific Biosciences of California	485	310.83 million	299.33 million	Optionable
TXG 10x Genomics	1,178	130.29 million	118.77 million	Optionable

PACB, TXG, AZTA, and CYRX Headlines

Recent News About These Companies

3 Analysts, 3 Trades to Make Today

September 22 at 5:00 PM | investorplace.com

10x Genomics Rises 3.4% as Raised Outlook and Analyst Reset Support Shares

September 22 at 1:51 PM | quiverquant.comQ

Beyond Meta, Cathie Wood’s ARKG Loads Up On These 4 Biotech Names

September 22 at 7:30 AM | finance.yahoo.com

Q2 rundown: 10x Genomics (NASDAQ:TXG) vs other life sciences tools & services stocks

September 22 at 7:30 AM | msn.com

10x Genomics Inc (TXG) Shares Surge 3.3% -- What GF Score of 56 Tells Investors

September 21 at 8:00 PM | gurufocus.com

10x Genomics (NASDAQ:TXG) Hits New 52-Week High - Here's What Happened

September 21 at 11:59 AM | marketbeat.com

Deutsche Bank Adjusts 10x Genomics Price Target to $70 From $40, Maintains Hold Rating

September 21 at 9:04 AM | marketscreener.comM

10x Genomics (TXG) Stock May Look Pricey As Oncology AI News Lands

September 19, 2026 | finance.yahoo.com

Tidal Investments LLC Makes New $1.28 Million Investment in 10x Genomics $TXG

September 19, 2026 | marketbeat.com

Corient Private Wealth LP Has $6.57 Million Stake in 10x Genomics $TXG

September 18, 2026 | marketbeat.com

10x Genomics (NASDAQ:TXG) Given Consensus Rating of "Hold" by Brokerages

September 17, 2026 | americanbankingnews.com

10x Genomics (NASDAQ:TXG) Receives Average Recommendation of "Hold" from Brokerages

September 17, 2026 | marketbeat.com

10x Genomics Inc Class A

September 16, 2026 | cnn.com

10x Genomics consensus price target raised 10.70% to $53.33

September 15, 2026 | msn.com

Engineers Gate Manager LP Sells 33,284 Shares of 10x Genomics $TXG

September 15, 2026 | marketbeat.com

Squarepoint Ops LLC Purchases Shares of 53,966 10x Genomics $TXG

September 15, 2026 | marketbeat.com

10x Genomics (NASDAQ:TXG) Hits New 1-Year High - Time to Buy?

September 15, 2026 | marketbeat.com

10x Genomics Stock (TXG) Opinions on Insider Selling and Atera Platform

September 12, 2026 | quiverquant.comQ

Adam Taich Sells 46,388 Shares of 10x Genomics (NASDAQ:TXG) Stock

September 12, 2026 | insidertrades.com

Insider Selling: 10x Genomics (NASDAQ:TXG) CFO Sells $2,995,273.16 in Stock

September 11, 2026 | marketbeat.com

UBS Sticks to Its Hold Rating for 10x Genomics (TXG)

September 11, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PACB, TXG, AZTA, and CYRX Company Descriptions

Azenta NASDAQ:AZTA

$34.28 +0.53 (+1.57%)

Closing price 09/22/2026 04:00 PM Eastern

Extended Trading

$33.83 -0.45 (-1.32%)

As of 04:30 AM Eastern

Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated cold storage solutions, consumables and instruments, controlled rate thawing devices, and temperature-controlled storage and transportation solutions. This segment also provides sample management solutions, such as consumable vials and tubes, polymerase chain reaction, plates, instruments for supporting workflows, and informatics. The Life Sciences Services segment provides genomic services, that includes gene sequencing and gene synthesis services; and sample repository solutions, such as on-site and off-site sample storage, cold chain logistics, sample transport and collection relocation, bio-processing solutions, disaster recovery and business continuity, and biospecimen procurement services, as well as project management and consulting services for genomic analysis and the management and care of biological samples used in pharmaceutical, biotech, healthcare, clinical, and academic research, and development sectors. It serves a range of life science customers, including pharmaceutical companies, biotechnology companies, biorepositories, and research institutes. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.

CryoPort NASDAQ:CYRX

$17.57 -0.05 (-0.28%)

Closing price 09/22/2026 04:00 PM Eastern

Extended Trading

$17.76 +0.19 (+1.08%)

As of 09/22/2026 07:30 PM Eastern

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

Pacific Biosciences of California NASDAQ:PACB

$1.47 +0.11 (+8.09%)

Closing price 09/22/2026 04:00 PM Eastern

Extended Trading

$1.46 -0.01 (-1.02%)

As of 04:29 AM Eastern

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

10x Genomics NASDAQ:TXG

$80.70 +1.60 (+2.02%)

Closing price 09/22/2026 04:00 PM Eastern

Extended Trading

$81.88 +1.18 (+1.46%)

As of 04:33 AM Eastern

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PACB, TXG, AZTA, and CYRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PACB, TXG, AZTA, and CYRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PACB, TXG, AZTA, and CYRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PACB, TXG, AZTA, and CYRX Company Descriptions

Azenta NASDAQ:AZTA

CryoPort NASDAQ:CYRX

Pacific Biosciences of California NASDAQ:PACB

10x Genomics NASDAQ:TXG

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PACB, TXG, AZTA, and CYRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PACB, TXG, AZTA, and CYRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PACB, TXG, AZTA, and CYRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PACB, TXG, AZTA, and CYRX Company Descriptions

Azenta NASDAQ:AZTA

CryoPort NASDAQ:CYRX

Pacific Biosciences of California NASDAQ:PACB

10x Genomics NASDAQ:TXG

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools